Abstract
Arterial hypertension is the most common cardiovascular disease which is usually caused by combination of several multifactorial abnormalities, including autonomic nervous system function, renin-angiotensin-aldosterone system (RAAS), baroreceptor reflexes, genetic factors, psychological stress, environmental and dietary factors (1). Along with abovementioned reasons some vasoactive peptides, especially endothelin-1 (E1), a substance with vasoconstrictor properties, is an important regulator of the vascular tone acting in physiological antagonism with atrial natriuretic hormone, prostacyclin and other vasodilator agents (2). The role of E- 1 in hypertension has attracted increasing interest over the past few years. It has been established that the presence of an intact endothelium is crucial for the action of several vasoactive agents (3), however less is known about endothelial function in healthy subjects, borderline hypertension or hypertensive patients (4). Studies of E-1 in established mild to severe hypertension have shown conflicting results, because the E1 levels reported in the different studies cannot be compared directly because of differences in antibody characteristics and comparatively small number of participant groups (5, 6). However, the multiple regression analyses further strengthen the link between blood pressure and endothelin levels, consistently showing that diastolic blood pressure (DBP) had the highest impact of the variables studied (4).
References
2. Bonhomme M. C., Cantin M, Garsia R. Relaxing effect of atrial natriuretic factor on endothelin precontracted vascular strips. Proc. Soc. Exp. Biol. Med. 1989, 191:305- 315.
3 . Vanhoutte P. M. Endothelium and control of vascular function. Hypertension. 1989, 13: 658-667.
4. Lemne C.E., Lundberg T, Theodorsson T, Faire U.D. Increased basal concentrations of plasma endothelin in borderline hypertension. J. of Hypertension. 1994, 12:1069- 1074.
5. Schiffrin E.L., Thibault G: Plasma endothelin in human essential hypertension. Am. J. Hypertension. 1991.4: 303-308.
6. Kohno M, Yasunari K, Murakawa K. L. et al. Plasma Immunoreactive Endothelin in Essential Hypertension. Am. J. Med. 1990. 88:614-618.
7. Yanagisava M, Kurihare H, Kimura S. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988. 332:441-415.
8. Pemow J., Franco-Cerecedo A, Matran R. et al. Effect of endothelin-1 on regional vascular resistance in the pig. J. Cardiovasc. Pharmacol. 1989, 13(Suppl. 5): S205-S206.
9. Schichiri M, Hirata Y, Ando K: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension. 1990.15: 493-496.
10. Schiffrin E.L. Role of Endothelin-1 in Hypertension. 1999. 34:876-881.
11. Li J.S., Schiffrin E.L. Effect of chronic treatment of adult SHR with an endothelin receptor antagonist. Hypertension. 1995.25(part I): 495-500.
12. Cargnelli G, Rossi G, Bova S. et al, In vitro vascular reactivity to endothelin: a comparison between young and old normotensive and hypertensive rats. Clin. Exp. Hypertension A. 1990. 12:1437-1451.
13. Schiffrin E. L., Lariviere R, Li J.S. et al. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in SHR. Hypertension. 1995. 25(2): 769-773.
14. Li J, S, Schurch W, Schiffrin E. Renal and vascular effect of chronic endothelin receptor antagonism in malignant hypertensive rats. Am. J. Hypertens. 1996. 9: 803-811.
15. Intengan H. D, He G, Schiffrin E.L. Effect of V1 vasopressin antagonism on small artery structure and vascular expression of preproendotellin-1 in DOCA-salt hypertensive rats. Hypertension. 1998. 32:770-777.
16. Sventek P, Turgeon a, Garcia R, Schiffrin E. L. Vascular and cardiac overexpression of endothelin-1 gene in onekidney one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J. Hypertension. 1996. 14:57-64.
17. Hocher B, George I, Rebstock J. et al. Endothelin system- dependent cardiac remodeling in renovascular hypertension. Hypertension. 1999. 33:816-622.
18. Schiffrin E. L., Thibault G. Plasma endothelin in human essential hypertension. Am. J. Hypertens. 1991.4:303-308.
19. Erguli S, Parish D. C, Puett D. et al. Racial differences in plasma E1 concentrations in individuals with essential hypertension. Hypertension. 1996. 28:652-655.
20. Noll G, Wenzel R.B, Schneider M. et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation. 1996. 93:866-869.
21. Dhaun N, Moorhouse R, Iain M. et al. Diurnal variation in blood pressure and arterial stiffness in chronic kidney disease: The role of endothelin-1. Hypertension. 214. 64: 296-304.
22. Stow L. R, Richards J, Cheng K.Y. et al. The circadiab protein period 1 contributes to blood pressure control and coordinately regulates renal sodium transport genes. Hypertension. 2012. 59:1151-1156.
23. Parvanova A, Van de Meer I. M, Iliev I. et al. Effect on blood pressure of combine inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomized crossover, double-blind, placebo-controlled trial. Lancet. Diabetes Endocrinol. 2013. 1:19-27.
24. Dhaun N, Melville V, Kramer W. et al. The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment. British J. Clin. Pharmacol. 2007. 64: 733-737.
25. Dhaun N, Macintyre I.M, Melville V. Effects of endothelin receptor antagonism relate to the degree of reninangiotensin system blockade in chronic proteinuric kidney disease. Hypertension. 2009. 54:e19-e20.
26. Uzu T, Kimura G. Diuretics shift circadian rhythm og blood pressure from nondipper to dipper in essential hypertension. Circulation. 1999. 100:1635-1638.
27. Dhaun N, Goddard J, Webb D. J. The endothelin system and its antagonism in chronic kidney disease. J. Am. Soc. Nephrol. 2006. 17:943-955.
28. Nikolaeva S, Pradervand S, Genteno G. et al. The circadian clock modulates renal sodium handling. J. Am. Soc. Nephrol. 2012. 23:1019-1026.
29. Bugaj V, Pochynyuk O, Mironova E. et al. Regulation of the epithelial Na+-channel by endothelin-1 in rat collecting duct. Am. J. Phys. Renal Physiol. 2008. 295:F1063- F1070.
30. Ahn D, Ge Y, Stricklett P. K. et al. Collecting ductspecific knockout of endothelin-1 causes hypertension and sodium retention. J. Clin. Invest. 2004.114:504-511.
31. Chen D.D, Dong Y. G. and Chen A.F. Endothelin-1 critically contribute to EPC reduction and dysfunction via ETA/NADPH oxidase pathway-induced oxidative stress in salt sensitive hypertension. Hypertension. 2012. 59(5): 1037- 1043.
32. Lemne C, Vesterqvist O, Egberg N.et al. Platelet activation of prostacyclin release in essential hypertension. Prostaglandines. 1992. 44:219-235.